换一批WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
第一作者：
Chen-Xu,Ni
第一单位：
School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
作者：
医学主题词
生物碱类(Alkaloids);动物(Animals);抗肿瘤药(Antineoplastic Agents);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 肝细胞(Carcinoma, Hepatocellular);细胞系, 肿瘤(Cell Line, Tumor);细胞增殖(Cell Proliferation);剂量效应关系, 药物(Dose-Response Relationship, Drug);多柔比星(Doxorubicin);抗药性, 肿瘤(Drug Resistance, Neoplasm);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);人类(Humans);半数抑制浓度(Inhibitory Concentration 50);肝肿瘤(Liver Neoplasms);男(雄)性(Male);小鼠, 近交BALB C(Mice, Inbred BALB C);小鼠, 裸(Mice, Nude);肿瘤干细胞(Neoplastic Stem Cells);表型(Phenotype);原癌基因蛋白质c-akt(Proto-Oncogene Proteins c-akt);喹嗪类(Quinolizines);时间因素(Time Factors);肿瘤负荷(Tumor Burden);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays);β连环素(beta Catenin)
DOI
10.18632/oncotarget.12822
PMID
27783993
发布时间
2018-11-13
- 浏览4
Oncotarget
79544-79556页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
